Hanns Mohler
Overview
Explore the profile of Hanns Mohler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
2391
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Majchrzak-Stiller B, Buchholz M, Peters I, Waschestjuk D, Strotmann J, Hohn P, et al.
J Cell Mol Med
. 2023 Jun;
27(14):2082-2092.
PMID: 37390227
GP-2250, a novel anticancer agent, severely limits the energy metabolism, as demonstrated by the inhibition of hexokinase 2 and glyceraldehyde-3-phosphate dehydrogenase and a decrease of ATP. Rescue experiments with supplementary...
2.
Luscher B, Mohler H
F1000Res
. 2019 Jul;
8.
PMID: 31275559
The GABAergic deficit hypothesis of depression states that a deficit of GABAergic transmission in defined neural circuits is causal for depression. Conversely, an enhancement of GABA transmission, including that triggered...
3.
Benke D, Mohler H
Neuropharmacology
. 2017 Aug;
136(Pt A):46-55.
PMID: 28764992
Animal studies of several single-gene disorders demonstrate that reversing the molecular signaling deficits can result in substantial symptomatic improvements in function. Focusing on the ratio of excitation to inhibition as...
4.
Mohler H, Rudolph U
F1000Res
. 2017 Feb;
6.
PMID: 28232865
Learning and memory are dependent on interactive excitatory and inhibitory mechanisms. In this review, we discuss a mechanism called disinhibition, which is the release of an inhibitory constraint that effectively...
5.
Mohler H
Adv Pharmacol
. 2015 Jan;
72:1-36.
PMID: 25600365
The study of the psychopharmacology of benzodiazepines continues to provide new insights into diverse brain functions related to vigilance, anxiety, mood, epileptiform activity, schizophrenia, cognitive performance, and autism-related social behavior....
6.
Mohler H, Pfirrmann R, Frei K
Int J Oncol
. 2014 Sep;
45(4):1329-36.
PMID: 25175943
Targeting the oxygen stress response pathway is considered a promising strategy to exert antineoplastic activity in a broad spectrum of tumor types. Supporting this view, we summarize the mechanism of...
7.
Mohler H
Neurochem Res
. 2014 Apr;
39(6):1032-6.
PMID: 24715673
By binding to the benzodiazepine site, diazepam binding inhibitor (DBI) is associated with negative allosteric modulation (NAM) of GABAA receptors (Costa and Guidotti in Life Sci 49:325-344, 1991). However, the...
8.
Rudolph U, Mohler H
Annu Rev Pharmacol Toxicol
. 2013 Oct;
54:483-507.
PMID: 24160694
The γ-aminobutyric acid (GABA) system plays a pivotal role in orchestrating the synchronicity of local networks and the functional coupling of different brain regions. Here we review the impact of...
9.
Mohler H
Biochem Pharmacol
. 2012 Aug;
84(8):994-9.
PMID: 22898099
The cognitive deficits in Down syndrome (DS) are attributed to an excessive hippocampal inhibition, which obstructs neuronal plasticity and normal learning and memory, a view which is largely based on...
10.
Benke D, Mohler H
Curr Protoc Pharmacol
. 2012 Feb;
Chapter 1:Unit1.16.
PMID: 22294164
This unit describes ligand binding assays for the characterization of the benzodiazepine (BZ) site of GABA(A) receptors in the central nervous system. The Basic Protocol provides a procedure for analyzing...